Post-Treatment Surveillance for Stage IB1 Cervical Cancer

Evidence-Based Surveillance Duration

The National Comprehensive Cancer Network and American College of Obstetricians and Gynecologists recommend that women treated for cervical cancer continue annual vaginal cytology screening for at least 20-25 years after radical hysterectomy, regardless of patient age at the end of this period, due to the persistent risk of recurrence and vaginal dysplasia 1, 2, 3
The American College of Obstetricians and Gynecologists suggests that women with a history of cervical cancer should continue screening indefinitely as long as they remain in reasonably good health without life-limiting chronic conditions, with no upper age limit for screening 2, 4, 3

Women with cervical cancer history have a significantly increased risk for vaginal intraepithelial neoplasia (VAIN) and vaginal cancer compared to the general population, with a high-risk HPV testing combined with vaginal cytology significantly increasing detection of VAIN and recurrence 4, 3

The National Comprehensive Cancer Network recommends a surveillance schedule of every 3-4 months with vaginal cytology and thorough pelvic examination for the first 2 years, every 6 months for years 3-5, and annually for years 6-20 (or 25) 5, 1, 2, 3
The American College of Obstetricians and Gynecologists suggests continuing annual screening indefinitely if the patient remains in good health, beyond 20-25 years 2, 4, 3

Women with hysterectomy for benign indications should never receive vaginal cytology screening, as it provides zero benefit, whereas women with CIN II/III history require the same 20-25 year surveillance as invasive cancer patients 4, 3, 6, 1, 2, 3, 6

The National Comprehensive Cancer Network advises against discontinuing screening at 20 years if the patient is younger than 65-70 years old, and against applying average-risk screening cessation guidelines to cervical cancer survivors, as they are permanently high-risk 1, 2, 3, 2, 3
The American College of Obstetricians and Gynecologists recommends maintaining high clinical suspicion and thorough pelvic examination, as cytology alone has limited sensitivity for detecting recurrence, and educating patients about recurrence symptoms 5, 5

The National Comprehensive Cancer Network and American College of Obstetricians and Gynecologists recommend confirming through pathology reports that hysterectomy was radical and performed for stage IB1 squamous cell carcinoma, documenting the date of surgery, and maintaining records of all surveillance results to track the pattern of findings over time 3, 1, 2, 3, 3

The American College of Obstetricians and Gynecologists and other experts recommend beginning screening every 4-6 months immediately after hysterectomy until three documented, consecutive, technically satisfactory normal/negative vaginal cytology tests are achieved within an 18-24 month period, for patients with a history of cervical carcinoma in situ, in order to detect potential recurrence or vaginal intraepithelial neoplasia (VAIN) early 7, 8, 9, 10, 11

Cervical carcinoma in situ (CIN2/3) is explicitly NOT considered a benign indication for hysterectomy, and patients with this history fall into the high-risk category requiring extended surveillance, according to the American College of Obstetricians and Gynecologists and other experts 7, 8, 9, 11
Women hysterectomized for truly benign disease (such as fibroids or prolapse) should not receive vaginal cytology screening, as it provides no benefit, whereas those with a history of CIN2/3 or cancer require at least 20-25 years of screening 8